The drugs industry is an enormous multibillion businesses encompassing an immense number of companies involved in the design, production and marketing of drugs worldwide. According to the type of drugs the market can be dived into the following segments: diabetes, antifungal, antidepressant, antithrombotic, hepatitis drugs, analgesics and a far more.
Currently, the drugs market is undergoing a recovery phase in the wake of the recent decline provoked by the economic slump. The market growth is spurred by increasing demand for drugs across the globe, rising incidence of chronic as well as infectious diseases, population ageing, product innovations and constant technological advancements. North America and Europe are the most prominent regional markets. Bristol-Myers Squibb, Pharmacia, GlaxoSmithKline, Merck & Co, Novartis, Eli Lilly, Pfizer, Johnson & Johnson, Allergan, Schering-Plough, Bayer and Abbott Labs are amid global drugs arena giants.
A huge collection of the research reports covering the drugs market at different geographies can be found under this MarketPublishers’ catalogue. The researches provide comprehensive assessment of the market, characterize major market trends and disclose essential market indicators. The reports describe the competitive scenario and indicate top market players. In addition, future prospects for the drugs market are thoroughly studied in the research reports.
Publications found:
9,295
Sort by:
Retinoic Acid Receptor (RAR) - Drugs in Development, 2021
US$ 3,000.00
Retinoic Acid Receptor (RAR) - Drugs in Development, 2021 SUMMARY Retinoic Acid Receptor (RAR) - Drugs in Development, 2021 provides in depth analysis on Retinoic Acid Receptor (RAR) targeted pipeline...
April 2021
35 pages
Retinoid X Receptor (RXR) - Drugs in Development, 2021
US$ 3,000.00
Retinoid X Receptor (RXR) - Drugs in Development, 2021 SUMMARY Retinoid X Receptor (RXR) - Drugs in Development, 2021 provides in depth analysis on Retinoid X Receptor (RXR) targeted pipeline therapeu...
April 2021
30 pages
Retinopathy (Ophthalmology) - Drugs in Development, 2021
US$ 2,000.00
Retinopathy (Ophthalmology) - Drugs in Development, 2021 SUMMARY Retinopathy (Ophthalmology) - Drugs in Development, 2021 provides an overview of the Retinopathy pipeline landscape. The report provide...
April 2021
40 pages
Sarcoidosis (Immunology) - Drugs in Development, 2021
US$ 2,000.00
Sarcoidosis (Immunology) - Drugs in Development, 2021 SUMMARY Sarcoidosis (Immunology) - Drugs in Development, 2021 provides an overview of the Sarcoidosis pipeline landscape. The report provides comp...
April 2021
45 pages
Scar (Dermatology) - Drugs in Development, 2021
US$ 2,000.00
Scar (Dermatology) - Drugs in Development, 2021 SUMMARY Scar (Dermatology) - Drugs in Development, 2021 provides an overview of the Scar pipeline landscape. The report provides comprehensive informati...
April 2021
55 pages
Sclerostin (SOST) - Drugs in Development, 2021
US$ 3,000.00
Sclerostin (SOST) - Drugs in Development, 2021 SUMMARY Sclerostin (SOST) - Drugs in Development, 2021 provides in depth analysis on Sclerostin (SOST) targeted pipeline therapeutics. The report provide...
April 2021
35 pages
Sepsis (Infectious Disease) - Drugs in Development, 2021
US$ 2,500.00
Sepsis (Infectious Disease) - Drugs in Development, 2021 SUMMARY Sepsis (Infectious Disease) - Drugs in Development, 2021 provides an overview of the Sepsis pipeline landscape. The report provides com...
April 2021
230 pages
Septic Shock (Other Diseases) - Drugs in Development, 2021
US$ 2,000.00
Septic Shock (Other Diseases) - Drugs in Development, 2021 SUMMARY Septic Shock (Other Diseases) - Drugs in Development, 2021 provides an overview of the Septic Shock pipeline landscape. The report pr...
April 2021
50 pages
